ARTICLE | Clinical News
Reolysin regulatory update
April 6, 2015 7:00 AM UTC
The European Commission granted Orphan Drug designation to Reolysin from Oncolytics to treat ovarian, fallopian tube and primary peritoneal cancers. The formulation of human reovirus type 3 is in Phas...